A study of allogeneic mesenchymal precursor cells with corrective heart surgery in children under the age of 5 with hypoplastic left heart syndrome (HLHS)

Trial Profile

A study of allogeneic mesenchymal precursor cells with corrective heart surgery in children under the age of 5 with hypoplastic left heart syndrome (HLHS)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2017 New trial record
    • 03 Apr 2017 According to a Mesoblast media release, the United States Food and Drug Administration (FDA) has cleared the commencement of this trial. This trial is sponsored and funded by the Boston Childrens Hospital with support from Bulens and Capozzi Foundation and the Ethan Lindberg Foundation. Dr. Sitaram Emani is Principal Investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top